[
    [
        {
            "time": "2018-09-13",
            "original_text": "How Companies Are Getting Ready for Hurricane Florence",
            "features": {
                "keywords": [
                    "Hurricane Florence",
                    "Companies",
                    "Ready"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "insurance",
                    "utilities"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "How Companies Are Getting Ready for Hurricane Florence",
                "Correlation": 3,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-09-14",
            "original_text": "Pfizer's Drug Combo Betters Survival in Kidney Cancer Study",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Drug Combo",
                    "Kidney Cancer",
                    "Study"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Pfizer's Drug Combo Betters Survival in Kidney Cancer Study",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-09-15",
            "original_text": "Dow Movers: INTC, CVX",
            "features": {
                "keywords": [
                    "Dow Movers",
                    "INTC",
                    "CVX"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology",
                    "energy"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Dow Movers: INTC, CVX",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-09-16",
            "original_text": "The Outlook for AstraZeneca Is Positive, But It’s Too Early to Pull the Trigger",
            "features": {
                "keywords": [
                    "AstraZeneca",
                    "Positive Outlook",
                    "Early"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Outlook for AstraZeneca Is Positive, But It’s Too Early to Pull the Trigger",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-09-17",
            "original_text": "Exact Sciences Posted 52.2% Returns in the Last Month",
            "features": {
                "keywords": [
                    "Exact Sciences",
                    "Returns",
                    "Last Month"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Exact Sciences Posted 52.2% Returns in the Last Month",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-09-18",
            "original_text": "Pfizer's Drug Combo Betters Survival in Kidney Cancer Study",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Drug Combo",
                    "Kidney Cancer",
                    "Study"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Pfizer's Drug Combo Betters Survival in Kidney Cancer Study",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]